01 February 2024
01 February 2024
The upcoming OCT West Coast 2024 conference will feature experts talking about emerging techologies, clinical trial operations for pharma and medical devices, and patient participation in studies.
The sabatolimab trial failed to meet its primary endpoint with Novartis saying the termination allows prioritisation of key programmes.
The shelving of Biogen’s troubled Alzheimer’s drug caps a turbulent journey, with Leqembi now receiving the company’s full attention.
Vabysmo was well tolerated with the safety profile, in line with prior trials.
Musk announced Neuralink's first sucessful human BCI implant on Sunday, but can the company live up to the hype?
The FDA has granted an orphan drug designation to Revolo’s ‘1104, with plans for a Phase IIb study later this year.
The RIVER-81 study is designed to assess RVU120 in combination with venetoclax for relapsed/refractory AML.
In the study, 71% of the subjects found the enhanced eIC more informative, with digital elements making them feel informed.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
